Drugs / APL-1202
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06435039 | Jun → Jul 2024 | — | Syneos Health | Terminated | No outcome recorded |
| Phase 1 | NCT04601766 | Oct → Dec 2020 | urinary bladder cancer | Asieris Pharmaceuticals (AUS) Pty Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03672240 | Nov 2018 → Oct 2019 | urinary bladder carcinoma | Asieris Pharmaceutical Technologies Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04498702 | May 2014 → Jan 2017 | non-invasive bladder urothelial carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04736394 | Sep 2021 → Mar 2025 | non-invasive bladder urothelial carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
| Phase 3 | NCT04490993 | Mar 2017 → May 2022 | urinary bladder carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06034015 Comparator | Sep 2023 → Jan 2024 | urinary bladder cancer | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04813107 Comparator | Dec 2021 → Nov 2023 | urinary bladder carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435039 ↗ |
| Route | Oral | “APL-1202 will be administered orally” NCT03672240 ↗ |